| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hao Tang, Yijun Cheng, Jinyan Huang, Jianfeng Li, Benyan Zhang, Zhe Bao W. Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists. Frontiers in endocrinology. vol 12. 2021-07-27. PMID:33776913. |
case report: temozolomide treatment of refractory prolactinoma resistant to dopamine agonists. |
2021-07-27 |
2023-08-13 |
Not clear |
| Hao Tang, Yijun Cheng, Jinyan Huang, Jianfeng Li, Benyan Zhang, Zhe Bao W. Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists. Frontiers in endocrinology. vol 12. 2021-07-27. PMID:33776913. |
therapeutic agents for refractory prolactinomas that are resistant to dopamine agonists (das) are troublesome, and surgery often only removes a large part of the tumor without complete remission. |
2021-07-27 |
2023-08-13 |
Not clear |
| Ramazan Sari, Meric A Altinoz, Eylem Burcu Kahraman Ozlu, Aydin Sav, Ayca Ersen Danyeli, Ozdil Baskan, Ozlem Er, Ilhan Elmac. Treatment Strategies for Dopamine Agonist-Resistant and Aggressive Prolactinomas: A Comprehensive Analysis of the Literature. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 53. issue 7. 2021-07-20. PMID:34282593. |
treatment strategies for dopamine agonist-resistant and aggressive prolactinomas: a comprehensive analysis of the literature. |
2021-07-20 |
2023-08-13 |
Not clear |
| Ramazan Sari, Meric A Altinoz, Eylem Burcu Kahraman Ozlu, Aydin Sav, Ayca Ersen Danyeli, Ozdil Baskan, Ozlem Er, Ilhan Elmac. Treatment Strategies for Dopamine Agonist-Resistant and Aggressive Prolactinomas: A Comprehensive Analysis of the Literature. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 53. issue 7. 2021-07-20. PMID:34282593. |
in this review, we aimed to define molecular endocrinological features of dopamine agonist-resistant and aggressive prolactinomas for designing future multimodality treatments. |
2021-07-20 |
2023-08-13 |
Not clear |
| Lukas Andereggen, Janine Frey, Robert H Andres, Markus M Luedi, Jan Gralla, Gerrit A Schubert, Jürgen Beck, Luigi Mariani, Emanuel Chris. Impact of primary medical or surgical therapy on prolactinoma patients' BMI and metabolic profile over the long-term. Journal of clinical & translational endocrinology. vol 24. 2021-07-02. PMID:34195008. |
while treatment with dopamine agonists (das) has been shown to improve these parameters, there is a lack of surgical series on its comparative effect in prolactinoma patients. |
2021-07-02 |
2023-08-13 |
Not clear |
| Zerui Wu, Yongzhi Zheng, Wanqun Xie, Qun Li, Yong Zhang, Bohan Ren, Lin Cai, Yijun Cheng, Hao Tang, Zhipeng Su, Zhe Bao W. The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists. Molecular and cellular endocrinology. vol 518. 2021-06-29. PMID:32946927. |
dopamine agonists (das), such as cabergoline and bromocriptine, are the first-line clinical treatment for prolactinomas. |
2021-06-29 |
2023-08-13 |
human |
| Xiong Wang, Li Ma, Qiao-Yan Ding, Wen-Yu Zhang, Yong-Gang Chen, Jin-Hu Wu, Hong-Feng Zhang, Xiu-Li Gu. Microglial NLRP3 inflammasome activation-mediated inflammation promotes prolactinoma development. Endocrine-related cancer. vol 28. issue 7. 2021-06-11. PMID:33974557. |
herein, two animal models of prolactinomas, namely oestrogen-treated rats and transgenic d2 dopamine receptor-deficient mice, were used. |
2021-06-11 |
2023-08-13 |
mouse |
| Muzaffar Ali, Lubna Mirz. Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment. AACE clinical case reports. vol 7. issue 3. 2021-06-08. PMID:34095489. |
morbid obesity due to prolactinoma and significant weight loss after dopamine agonist treatment. |
2021-06-08 |
2023-08-13 |
Not clear |
| Muzaffar Ali, Lubna Mirz. Morbid Obesity Due to Prolactinoma and Significant Weight Loss After Dopamine Agonist Treatment. AACE clinical case reports. vol 7. issue 3. 2021-06-08. PMID:34095489. |
our objective was to present a case of prolactinoma with morbid obesity, hypogonadism, and then significant weight loss after dopamine agonist treatment. |
2021-06-08 |
2023-08-13 |
Not clear |
| Emmanuelle Kuhn, Alexandra A Weinreich, Nienke R Biermasz, Jens Otto L Jorgensen, Philippe Chanso. Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature. European journal of endocrinology. vol 185. issue 1. 2021-05-31. PMID:33914699. |
prolactinomas frequently cause amenorrhoea, galactorrhoea and infertility and require dopamine agonist (da) treatment to normalize prolactin levels and hence, restore ovulation. |
2021-05-31 |
2023-08-13 |
Not clear |
| Etual Espinosa-Cárdenas, Miriam Sánchez-García, Claudia Ramírez-Rentería, Victoria Mendoza-Zubieta, Ernesto Sosa-Eroza, Moises Mercad. High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment? Endocrine. vol 70. issue 1. 2021-05-27. PMID:32548734. |
treatment with dopamine agonists (da) is highly effective in patients with prolactinomas. |
2021-05-27 |
2023-08-13 |
Not clear |
| Xueyan Wan, Zisheng Yan, Zhoubin Tan, Zhi Cai, Yiwei Qi, Liang Lu, Yu Xu, Juan Chen, Ting Le. MicroRNAs in Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology. 2021-05-25. PMID:34034260. |
micrornas in dopamine agonist-resistant prolactinoma. |
2021-05-25 |
2023-08-13 |
Not clear |
| Kunal Thakkar, Vijaya Sarathi, Nalini S Sha. Current Status of Diagnosis and Management for Functioning Pituitary Tumors: Part I. Neurology India. vol 68. issue Supplement. 2021-04-14. PMID:32611887. |
trans-sphenoidal surgical resection of tumor represents the first-line treatment for most tumor types, except for prolactinomas where medical therapy with dopamine agonists is preferred. |
2021-04-14 |
2023-08-13 |
Not clear |
| Manas K Panigrahi, Y B V K Chandrasekhar, Sudhindra Vootur. Current Status of Surgery in Management of Prolactinomas. Neurology India. vol 68. issue Supplement. 2021-04-14. PMID:32611891. |
although dopamine agonists are the current mainstay of management of prolactinomas, surgery was often preferred management option prior to 1980, before the advent of dopamine agonists. |
2021-04-14 |
2023-08-13 |
Not clear |
| Camille K Milton, Benjamin J Lee, Zoya A Voronovich, Andrew K Conner, Kibwei A McKinney, Edward T El Rassi, Jonea Lim, Chad A Glen. Prolactinoma extension as a contributing factor in dopamine agonist-induced CSF rhinorrhea: a systematic review of the literature. British journal of neurosurgery. 2021-03-30. PMID:33783287. |
prolactinoma extension as a contributing factor in dopamine agonist-induced csf rhinorrhea: a systematic review of the literature. |
2021-03-30 |
2023-08-13 |
Not clear |
| Camille K Milton, Benjamin J Lee, Zoya A Voronovich, Andrew K Conner, Kibwei A McKinney, Edward T El Rassi, Jonea Lim, Chad A Glen. Prolactinoma extension as a contributing factor in dopamine agonist-induced CSF rhinorrhea: a systematic review of the literature. British journal of neurosurgery. 2021-03-30. PMID:33783287. |
dopamine agonist-induced cerebrospinal fluid (csf) rhinorrhea is an uncommon treatment-related complication arising in 6.1% of prolactinoma patients treated with dopamine agonists. |
2021-03-30 |
2023-08-13 |
Not clear |
| Elle Vermeulen, Jean D'Haens, Tadeusz Stadnik, David Unuane, Kurt Barbe, Vera Van Velthoven, Sven Gläske. Predictors of dopamine agonist resistance in prolactinoma patients. BMC endocrine disorders. vol 20. issue 1. 2021-03-15. PMID:32429916. |
predictors of dopamine agonist resistance in prolactinoma patients. |
2021-03-15 |
2023-08-13 |
Not clear |
| Elle Vermeulen, Jean D'Haens, Tadeusz Stadnik, David Unuane, Kurt Barbe, Vera Van Velthoven, Sven Gläske. Predictors of dopamine agonist resistance in prolactinoma patients. BMC endocrine disorders. vol 20. issue 1. 2021-03-15. PMID:32429916. |
surgical resection of prolactinomas resistant to dopamine agonists is frequently incomplete due to fibrotic changes of the tumour under pharmacological therapy. |
2021-03-15 |
2023-08-13 |
Not clear |
| Elle Vermeulen, Jean D'Haens, Tadeusz Stadnik, David Unuane, Kurt Barbe, Vera Van Velthoven, Sven Gläske. Predictors of dopamine agonist resistance in prolactinoma patients. BMC endocrine disorders. vol 20. issue 1. 2021-03-15. PMID:32429916. |
in order to identify a subgroup of patients who may benefit from early surgery, we thought to investigate possible predictive factors of pharmacological resistance of prolactinomas to dopamine agonists. |
2021-03-15 |
2023-08-13 |
Not clear |
| Camille Hage, Roberto Salvator. Predictors of the Response to Dopaminergic Therapy in Patients With Prolactinoma. The Journal of clinical endocrinology and metabolism. vol 105. issue 12. 2021-02-26. PMID:32930718. |
withdrawal of dopamine agonist (da) therapy in patients with prolactinoma who are controlled by a small dose of medication is recommended by several guidelines. |
2021-02-26 |
2023-08-13 |
Not clear |